Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Soluble TNF and IL-2 receptors in patients with breast cancer

Petra Tesarova, Jan Kvasni‹cka, Anna Umlaufova, Hana Homolkova, Milan Jirsa, Vladimi’r Tesar

Med Sci Monit 2000; 6(4): BR661-667

ID: 508096

Available online:


Introduction: Cytokines were shown both to enhance tumour growth and formation of metastases and to inhibit proliferation of tumour cells. TNFa may mediate apoptosis and necrosis of cancer cells, while the exact role of IL-2 remains to be elucidated. Plasma levels of TNFa and TNF and IL-2 soluble receptors (sTNF-R, sIL-2R) should thus be in some relation to some biological characteristics of the breast cancer.
Material and methods: Plasma levels of TNFa, sTNF-R I and II and sIL-2R were measured in 31 women with different stages of breast cancer both before the institution of therapy and after 3 months of the treatment.
Results: Plasma levels of both types of sTNF-Rs were higher in patients with breast cancer than in controls (sTNF-R I - 2166.6±568.9 vs. 1121.3±260.6 pg/ml,p<0.001, sTNF-R II - 3792.8±958.9 vs. 1996.2±404.3 pg/ml, p<0.001) with no significant difference between clinical stages. Plasma levels of both sTNF-R (0.871, p<0.001) and sIL-2R tightly correlated with each other. Plasma levels of TNFa decreased after treatment (from 3.92±1.86 to 3.40±1.15 pg/ml, p<0.01), but plasma levels of sTNF-Rs and sIL-2R were not influenced by the therapy.
Conclusion: Plasma levels of soluble TNF receptors may thus serve as a non-specific marker of the untreated breast cancer. Their relation to other biologic characteristics of this tumour is not clear. It remains also to be clarified if the long-term treatment leads to the normalization of sTNF-Rs plasma levels.

Keywords: breast cancer, IL-2 receptor, TNF receptor, adhesion molecules, Cytokines